Reata Pharmaceuticals - RETA Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RETA shares.
View RETA analyst ratings or view top-rated stocks.

6 brokers have issued 12-month price targets for Reata Pharmaceuticals' shares. Their RETA share price forecasts range from $27.00 to $112.00. On average, they predict the company's stock price to reach $57.57 in the next year. This suggests a possible upside of 121.9% from the stock's current price.
View analysts price targets for RETA or view top-rated stocks among Wall Street analysts.

Reata Pharmaceuticals' stock was trading at $26.37 on January 1st, 2022. Since then, RETA shares have decreased by 1.6% and is now trading at $25.94.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our RETA earnings forecast.

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) issued its quarterly earnings data on Monday, August, 8th. The company reported ($2.02) earnings per share for the quarter, missing analysts' consensus estimates of ($1.90) by $0.12. The company had revenue of $0.76 million for the quarter, compared to analysts' expectations of $1.46 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 190.87% and a negative net margin of 3,045.98%. The firm's quarterly revenue was down 65.7% compared to the same quarter last year. During the same period last year, the firm earned ($2.00) EPS.

10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

(RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Shares of RETA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RETA stock can currently be purchased for approximately $25.94.

Reata Pharmaceuticals (NASDAQ:RETA) has a market capitalization of $946.73 million and generates $11.49 million in revenue each year. The company earns $-297,390,000.00 in net income (profit) each year or ($8.37) on an earnings per share basis.

The company employs 346 workers across the globe.

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The official website for the company is www.reatapharma.com. The company can be reached via phone at (972) 865-2219 or via email at ir@reatapharma.com.